Canagliflozin in Children with Type 2 Diabetes
Contact
Description
The goal of this study is to investigate the efficacy and safety of Canagliflozin (which is experimental) in children and adolescents ages 10 to 18 years old with Type 2 diabetes and poor control (i.e., an HbA1c of 6.5% to 10.5%). Study drug or placebo would be taken alone or with metformin or insulin as needed. Monitoring tests include blood, urine, physical exams, vital signs, blood sugar and ketone monitoring, diabetes management counseling.
Eligibility and criteria
IRB Number:
19-016066
Eligible age range:
Clinical trial phase:
Phase III
Official title:
Related specialties

We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.